DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00040521 (ClinicalTrials.gov)	April 2002	27/6/2002	Study Evaluating rhIL-11 in Active Crohn's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease	Crohn Disease;Inflammatory Bowel Disease	Drug: Recombinant Human Interleukin-11 (rhIL-11)	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	16 Years	N/A	Both		Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00040521
(ClinicalTrials.gov)

April 2002

27/6/2002

Study Evaluating rhIL-11 in Active Crohn's Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease

Crohn Disease;Inflammatory Bowel Disease

Drug: Recombinant Human Interleukin-11 (rhIL-11)

Wyeth is now a wholly owned subsidiary of Pfizer

NULL

Completed

16 Years

N/A

Both

Phase 2

United States